Alpha-synuclein (Syn) plays a central role in the pathogenesis of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Recent multicenter genetic studies have revealed that mutations in the glucocerebrosidase 1 (GBA1) gene, which are responsible for Gaucher's disease, are strong risk factors for PD and DLB. However, the mechanistic link between the functional loss of glucocerebrosidase (GCase) and the toxicity of Syn in vivo is not fully understood. In this study, we employed Drosophila models to examine the effect of GCase deficiency on the neurotoxicity of Syn and its molecular mechanism. Behavioral and histological analyses showed that knockdown of the Drosophila homologue of GBA1 (dGBA1) exacerbates the locomotor dysfunction, loss of dopaminergic neurons, and retinal degeneration of Syn-expressing flies. This phenotypic aggravation was associated with the accumulation of proteinase K (PK)-resistant Syn, rather than with changes in the total amount of Syn, raising the possibility that glucosylceramide (GlcCer), a substrate of GCase, accelerates the misfolding of Syn. Indeed, in vitro experiments revealed that GlcCer directly promotes the conversion of recombinant Syn into the PK-resistant form, representing a toxic conformational change.
(7)
. Glucocerebrosidase (GCase) is a lysosomal enzyme, which hydrolyzes the glycolipid glucosylceramide (GlcCer). Homozygous mutations in the GBA1 gene, which result in decreased enzyme activities, cause Gaucher's disease (GD), one of the lysosomal storage diseases. GD patients have a 21-fold increased life-time risk of developing parkinsonism (8) , and GD patients who exhibit parkinsonism were found to have Syn-positive LBs in their brains (9) . In addition, PD patients with a heterozygous GBA1 mutation more frequently develop diffuse LB pathology, which is associated with earlier disease onset, compared with those without GBA1 mutations (10) . These facts strongly suggest a tight link between Syn toxicity and GBA1 mutations. However, the molecular mechanisms as to how GBA1 mutations affect Syn toxicity in vivo are not fully understood.
In this study, we employed Drosophila models to examine the in vivo role of GCase deficiency in Syn-mediated neurotoxicity, as well as the molecular mechanisms involved. We found that knockdown of the Drosophila homologue of GBA1 (dGBA1) accelerates Syn neurotoxicity without any alterations in total Syn levels. Instead, the accumulation of proteinase K (PK)-resistant Syn was accelerated by dGBA1 knockdown, which correlated with the phenotypic aggravation. Furthermore, GlcCer, which is a substrate of GCase, directly promoted the formation of PK-resistant Syn. We therefore conclude that the aberrant interaction of Syn with GlcCer, which accumulates upon the loss of GCase activity, is a key event in the acquisition of toxic properties of Syn.
Results

GCase deficiency increases Syn toxicity in Drosophila
To investigate the effect of GCase deficiency on the neurotoxicity of Syn, we used transgenic RNAi flies that express an inverted repeat RNA (IR) targeting the Drosophila homologues of the by guest on November 7, 2016 http://hmg.oxfordjournals.org/ Downloaded from 5 GBA1 gene, namely, CG31148 (dGBA1a) or CG31414 (dGBA1b), which show 49% or 31% amino acid similarity to the human gene, respectively, under the control of the GAL4-UAS system. We first analyzed the effect of GCase deficiency in the brain, by using the flies expressing dGBA1a-IR (dGBA1a-RNAi flies) or dGBA1b-IR (dGBA1b-RNAi flies) under the pan-neuronal elav-GAL4 driver. The elav-GAL4 driver was chosen because the effect of the GBA1 mutation might not be limited to the DA neurons in the case of DLB (7), in which cholinergic neurons in the neocortex are also affected (11) . Compared with the flies expressing Ctr-IR (Ctr-RNAi flies), the brain lysates of dGBA1a-RNAi-a and dGBA1a-RNAi-b flies exhibited a 92% and 81% decrease in GCase activity, whereas those of dGBA1b-RNAi-a, dGBA1b-RNAi-b, and dGBA1b-RNAi-c flies exhibited a 28%-51% decrease (Fig. 1A) . We also confirmed that dGBA1a mRNA levels were decreased in the brains of the dGBA1a-RNAi flies to approximately 20% compared with Ctr-RNAi flies (Fig. 1B) . Therefore, we decided to use dGBA1a-RNAi flies in the subsequent experiments.
To examine whether GCase deficiency affects the toxicity of Syn in vivo, we crossed human wild-type Syn-expressing flies (Syn flies), which is a well-established PD model (12) , with the dGBA1a-RNAi flies to obtain flies co-expressing both Syn and dGBA1a-IR (Syn/dGBA1a-RNAi flies) in the nervous system. We performed the climbing assay to evaluate the effect of dGBA1 knockdown on the locomotor dysfunction of the Syn flies. Syn flies expressing Ctr-IR (Syn/Ctr-RNAi flies) exhibited a mild decline in climbing ability from 6 We performed immunohistochemical staining with an antibody against tyrosine hydroxylase (TH), which is an enzyme required for the biosynthesis of DA. We found that Syn/Ctr-RNAi flies have fewer DA neurons than EGFP/Ctr-RNAi flies at 6 weeks after eclosion ( Fig. 1D and E, EGFP/Ctr-RNAi vs Syn/Ctr-RNAi flies). Moreover, the loss of DA neurons in Syn flies was significantly exacerbated by dGBA1 knockdown in the protocerebral posterior lateral (PPL) cluster (Fig. 1E , Syn/Ctr-RNAi vs Syn/dGBA1a-RNAi-a or Syn/dGBA1a-RNAi-b flies), and this tendency of exacerbation was also seen in the protocerebral posterior medial (PPM) clusters (Fig. 1E) . Furthermore, the exacerbation of Syn toxicity by GCase deficiency was also observed with the retinal degeneration phenotype under the eye-specific GMR-GAL4 driver.
Syn/dGBA1a-RNAi flies, but not the other flies, exhibited thinning and vacuolization of the retinal tissue resulting from photoreceptor degeneration (Fig. 1F , middle and lower panels, and 
GCase deficiency accelerates the accumulation of proteinase K-resistant Syn
Since Syn has been reported to be degraded in lysosomes (13) (14) (15) , we hypothesized that the loss of GCase activity compromises the Syn-degrading function of lysosomes, resulting in Syn accumulation. To test whether the aggravation of Syn toxicity by GCase deficiency is caused by the accelerated accumulation of Syn proteins, we performed immunoblotting analysis. We found that the amounts of Syn in both the Triton X-100-soluble and -insoluble fractions are not significantly increased, but rather are almost unchanged by dGBA1 knockdown ( Fig. 2A-C) . Upon long-exposure of the membrane, we identified SDS-resistant bands (approximately 35 kDa), probably corresponding to dimers, in the Triton X-100-soluble fraction 7 (arrow in Fig. 2A) , and the amount of this dimer was decreased by dGBA1 knockdown. These results suggest that GCase deficiency does not result in the accumulation of Syn, and thus the impaired degradation of Syn in lysosomes is unlikely to be the mechanism responsible for the phenotypic aggravation of Syn-expressing flies upon dGBA1 knockdown.
From these results, we considered the possibility that not simply the total amount of Syn, but alterations in the toxic properties of Syn may contribute to the phenotypic aggravation of Syn/dGBA1a-RNAi flies. Prion-like conformational changes of Syn have been shown to be associated with the pathogenesis of PD (16, 17) , and these different Syn conformers can be distinguished biochemically by their susceptibility to PK digestion (18) .
Indeed, PK-resistant Syn accumulates in the brains of PD patients and animal models of PD, including mice and Drosophila, suggesting a significant role of PK-resistant Syn in disease pathogenesis (19) (20) (21) . We therefore treated fly head lysates with serial concentrations of PK and performed immunoblotting to assess the PK resistance of Syn. In Syn/Ctr-RNAi flies the immunoreactivity of Syn was considerably decreased by treatment with 1 μg/ml PK, and was almost completely abolished by treatment with more than 5 μg/ml PK (Fig. 2D) . In contrast, Syn/dGBA1a-RNAi-b flies showed residual Syn bands even upon treatment with 5 or 10 μg/ml PK. Quantification analyses revealed that the amounts of full-length Syn that remained after 1 μg/ml PK treatment are significantly increased in the Syn/dGBA1a-RNAi-b flies compared with those in the Syn/Ctr-RNAi flies (1.68-fold, p < 0.05, Fig. 2D ). Furthermore, the band patterns of the Syn fragments after PK digestion were altered upon dGBA1 knockdown, suggesting that GCase deficiency may promote conformational changes in Syn (16).
Immunohistochemical analyses of retinal sections also demonstrated that the immunoreactivity of PK-resistant Syn is increased in the Syn/dGBA1a-RNAi flies compared with Syn/Ctr-RNAi flies (Fig. 2E) . Interestingly, the accumulation of PK-resistant Syn increased by guest on November 7, 2016 http://hmg.oxfordjournals.org/ Downloaded from 8 with age in both the Syn/dGBA1a-RNAi and Syn/Ctr-RNAi flies (Fig. 2E) , which is consistent with the progressive decline in locomotor dysfunction (Fig. 1C) . Taken together, these results suggest that the accumulation of PK-resistant Syn may be responsible for the phenotypic aggravation seen in Syn/dGBA1a-RNAi flies.
Glucosylceramide promotes the formation of PK-resistant αSyn
Our results showing the accelerated accumulation of PK-resistant Syn in the Syn/dGBA1a-RNAi flies raised the possibility that GlcCer, a substrate of GCase, affects the conversion process of Syn into the PK-resistant form. We first examined whether GlcCer accumulation occurs upon dGBA1 knockdown. Thin-layer chromatography (TLC) analysis showed that the amounts of GlcCer was significantly increased in the heads of the dGBA1a-RNAi flies compared with those of the Ctr-RNAi flies, when co-expressed with either EGFP or Syn (Fig. 3A and B) . Moreover, immunohistochemical staining using a GlcCer antibody also showed the accumulation of GlcCer in the dGBA1a-RNAi flies ( Fig. 3C and D) , confirming that GCase deficiency leads to GlcCer accumulation in our fly model. We next tested whether GlcCer directly accelerates the formation of PK-resistant Syn, using an in vitro assay. Recombinant Syn was incubated with lipid dispersions consisting of phosphatidylcholine (PC) with or without GlcCer for 14 days, and after PK digestion, Syn was subjected to immunoblotting analyses. On day 1 (24 hr after incubation), the relative amounts of undigested Syn were almost equal between Syn incubated with GlcCer-containing PC and that incubated with PC only (Fig. 4A ). In contrast, on days 7 and 14, the relative amounts of undigested Syn incubated with GlcCer were significantly greater than that incubated with PC only ( Fig. 4B and C) , indicating resistance to PK digestion. In addition, we noted that the amounts of the approximately 35 kDa bands, probably corresponding to SDS-resistant Syn by guest on November 7, 2016 http://hmg.oxfordjournals.org/ Downloaded from dimers (arrows in Fig. 4 ), were also increased at 7 and 14 days after incubation with GlcCer ( Fig. 4B-D) , although the amounts of the Syn dimer were not increased, but rather decreased, in the Syn/dGBA1a-RNAi flies ( Fig. 2A) . These data strongly indicate that GlcCer directly promotes the conversion of Syn into the PK-resistant form.
β-galactosidase deficiency increases Syn toxicity in flies and GM1 ganglioside promotes the formation of PK-resistant Syn GD is one of lysosomal storage diseases (LSDs), in which the deficiency of specific lysosomal enzymes causes the accumulation of certain lipids and glycoproteins in lysosomes, resulting in various neurological and peripheral symptoms. Interestingly, Syn accumulation is also found in the brains of patients of several LSDs, including GM1 gangliosidosis, GM2 gangliosidosis, and Sanfilippo syndrome (22, 23) , as well as GD (24) . Moreover, it was shown that induced pluripotent stem cells (iPSC)-derived neurons from GBA1-associated PD patients exhibit decreased GCase activity, as well as β-galactosidase (β-Gal) activity compared with the isogenic gene-corrected controls (25) . These facts led us to examine whether knockdown of β-Gal accelerates Syn toxicity as in the case of dGBA1 knockdown.
We obtained fly lines carrying IR transgenes targeted to the Drosophila homologue of the β-galactosidase (dβ-Gal, approximately 41% amino acid similarity to human β-Gal) gene, which is responsible for GM1 gangliosidosis. We confirmed that the amounts of dβ-Gal mRNA in dβ-Gal-RNAi fly brains were decreased to less than 10% of that in Ctr-RNAi fly brains when expressed under the elav-GAL4 driver (Fig. 5A) . To assess the effect of dβ-Gal knockdown on Syn toxicity, we crossed the dβ-Gal-RNAi flies with Syn flies, and found that knockdown of dβ-Gal significantly exacerbates the locomotor dysfunction of αSyn flies (Syn/Ctr-RNAi vs Syn/dβ-Gal-RNAi-a or Syn/dβ-Gal-RNAi-b flies, Fig. 5B) . Moreover, the aggravation in climbing abilities of the Syn/dβ-Gal-RNAi flies was associated with an accumulation of PK-resistant Syn, as revealed by immunoblotting analysis (Fig. 5C ). To observe the direct effect of GM1 ganglioside (GM1), a substrate of β-Gal, on the formation of PK-resistant Syn, we performed an in vitro assay and found that GM1-containing liposomes promoted the conversion of Syn into the PK-resistant form, similarly to GlcCer-containing liposomes ( Fig.   5D-F) . In contrast to GlcCer, dimer formation was not affected by GM1-containing liposomes (Fig. 5G ). These findings suggest that an increase in Syn neurotoxicity by β-Gal deficiency is also mediated by an increase in the PK resistance of αSyn, supporting our hypothesis that aberrant interactions of αSyn with glycolipids trigger the toxic conversion of αSyn, resulting in an increase in neurotoxicity in vivo.
Discussion
In the present study, we investigated the molecular mechanisms underlying the effect of GCase deficiency on Syn toxicity. We demonstrated that loss of GCase function exacerbates Syn neurotoxicity in vivo and that this aggravation is associated with the accelerated accumulation of PK-resistant Syn. In addition, GlcCer, which was accumulated in the brain of dGBA1 knockdown flies, directly promoted the formation of PK-resistant Syn, suggesting that the accumulation of GlcCer by GCase deficiency promotes the toxic conversion of Syn, leading to exacerbation of its neurotoxicity.
The phenotypic aggravation by GCase deficiency in Syn flies was associated with the accumulation of PK-resistant Syn, rather than with changes in the total amount of Syn, suggesting that the production of this PK-resistant Syn species might play a key role in the neurotoxicity. Although we did not directly demonstrate the toxicity of PK-resistant Syn, there was a tight association between the neurotoxicity of Syn and its PK resistance. PK-resistant Syn oligomers that are formed as an intermediate conformer in the course of in vitro Syn fibrillization have been shown to cause oxidative stress in primary neurons at much higher levels than non-PK-resistant oligomers (26) . Guo et al. found that two kinds of Syn fibrils exhibiting different vulnerabilities to PK digestion can be isolated from repetitive seeded fibrillization, and the Syn strain more resistant to PK digestion was more toxic to neurons (17) .
In addition, Syn fibril strains produced using different buffers showed different vulnerabilities to PK digestion, and their toxicities were associated with their resistance to PK digestion (16).
Interestingly, it was also demonstrated that Syn fibrils with different levels of PK resistance have different structures, cross-seeding abilities, and propagation properties both in vitro and in vivo, all of which are reminiscent of the properties of prions (16, 17) . Therefore, it is possible that the accelerated formation of PK-resistant Syn that we observed in the GCase-deficient flies represents the "prion-like conversion" of Syn, and that this toxic species leads to phenotypic aggravation by promoting the prion-like seeding and propagation of Syn.
The idea that Syn is degraded in lysosomes (13-15) has led to several studies based on the hypothesis that loss of GCase activity compromises the Syn-degrading function of lysosomes, resulting in Syn accumulation. Several groups demonstrated that decreased GCase activity results in increased amounts of Syn, using cultured neurons, human iPSC-derived neurons from GBA1 mutation carriers, and mice treated with a GCase inhibitor (25, 27, 28) . On the other hand, two other groups reported that GCase activity does not correlate with the amount of Syn in neuronal cells (29) , whereas the expression of a mutant GCase that maintains its enzyme activity increases the amount of Syn (30), favoring a gain-of-function mechanism in the pathogenesis of GBA1-associated PD. In our fly model, the amount of total Syn was not significantly increased by GCase deficiency, despite the phenotypic aggravation (Fig. 1C-G and Fig. 2A-C) . However, a recent study using PD model mice with a GBA1 mutation showed that 12 the total amount of Syn in the brain lysates was not increased, but the rate of Syn degradation assessed by pulse-chase experiments was decreased in primary neurons from the same mice (31).
Thus, we could not completely exclude the possibility that Syn degradation is compromised by lysosomal dysfunction, even though changes in the total amount of Syn were not detected.
In addition to the fly model experiments, we further demonstrated by in vitro experiments that GlcCer directly promotes the formation of PK-resistant Syn (Fig. 4) , as a mechanism for the increased accumulation of PK-resistant Syn in the dGBA1a-RNAi flies.
These results are consistent with a previous report showing a direct effect of GlcCer on the stability of Syn oligomers (28) . Moreover, we also found a significant increase in Syn dimers by the incubation of Syn with GlcCer-containing liposomes (Fig. 4B-D) , which is consistent with the finding that the amount of Syn dimers was significantly increased in GD patients (32) .
We also showed that β-Gal knockdown exacerbates the locomotor dysfunction of Syn flies, and GM1 directly promotes the PK resistance of Syn (Fig. 5) , supporting our hypothesis that aberrant interactions of αSyn with glycolipids trigger the toxic conversion of αSyn, resulting in increased neurotoxicity in vivo. It has been demonstrated that GM1 specifically binds to Syn and induces its oligomerization, thereby inhibiting its fibrillation (33) . Interestingly, a recent report showed that iPSC-derived neurons from GBA1-associated PD patients exhibit not only decreased GCase activity, but also decreased β-Gal activity, which can be rescued by zinc-finger nuclease-mediated gene correction, implying a crosstalk between GCase and β-Gal activity (25) . Taken together, it is possible that a loss of β-Gal activity also contributes to the acceleration of Syn toxicity in GBA1-associated PD. It is noted that the direct binding of GM1 to the amyloid β protein also triggers its toxic conversion (34), implying a common or similar role of glycolipids in the conversion of neurodegenerative disease-related proteins from their non-toxic to toxic forms.
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Then, where in a cell does the accumulated GlcCer interact with Syn to convert it into a PK-resistant form? One possibility is that Syn is transported into lysosomes via macroautophagy or chaperone-mediated autophagy (13) (14) (15) , where it interacts with accumulated GlcCer. Then, GlcCer-associated Syn is secreted from the cells, taken up by itself or by the surrounding cells, and accumulates in the cytosol (35, 36) . The other possibility is that the accumulated GlcCer in the lysosome leaks into the cytosol, and interacts with Syn in the cytosol, as the leakage of GlcCer into the cytosol has been reported in both GD patients and GD model mice (37, 38) . There have been no reports to date of the level of GlcCer in the brain of PD patients with a GBA1 mutation. However, in iPSC-derived neurons from two PD patients with a heterozygous GBA1 mutation (RecNcil/wt and N370S/wt), which causes an approximately 50% decrease in GCase activity, the amount of GlcCer has been reported to be about 2-fold higher than isogenic gene-corrected iPSC-derived neurons (25) . Furthermore, GlcCer was reported to be accumulated in the brains of GD patients (37) in which GCase activity was decreased (by 80%-90%) (39, 40) . GCase activity was also found to be moderately decreased in the brains of GBA1 mutant carrier PD patients (58% decrease in the substantia nigra) (41, 42) . Collectively, these data suggest that GlcCer accumulates in the brains of GBA1 mutation carrier PD patients.
Our present study focused on the loss-of-function aspect of GBA1 mutations, but there is another possibility arguing the gain-of-function toxicity of mutant GCase, because most mutant GCases are prone to misfold in the ER. Human skin fibroblasts derived from GD patients and carriers are reported to induce the unfolded protein response, which is also observed in Drosophila models of GD expressing human mutant GCase (43) . Ambroxol, a potential pharmacological chaperone for mutant GCase has been shown to ameliorate both ER stress and the phenotypes of these Drosophila models (44). Interestingly, ambroxol treatment 14 also suppresses the misfolding of mutant GCase, subsequently resulting in an enhancement of cellular GCase activity (45) . Therefore, chemical chaperone therapy can be expected to exert beneficial effects against GD, via the amelioration of both the gain-of-function aspect through ER stress and the loss-of-function aspect through decreased GCase activity. Since ER stress is suggested to be involved in the neurodegeneration that occurs in PD (46) (47) (48) , the synergistic effects of chemical chaperone therapy would also be effective for GBA1-associated PD patients, through the suppression of both ER stress and the toxic conversion of Syn by GlcCer accumulation.
In summary, our study revealed that the loss of function of GCase accelerates the toxic conversion of Syn via an interaction with its substrate glycolipid GlcCer. Therefore, prevention of the conversion of Syn to PK-resistant forms by altering GlcCer metabolism might be a promising approach as a disease-modifying therapy for PD and DLB.
Materials and Methods
Fly stocks.
Flies were grown on standard cornmeal medium at 25 ˚C. Transgenic fly lines bearing
UAS-h[WT]Syn (#8146) (12), UAS-EGFP (#6658), elav-GAL4 c155 (#458), and UAS-GFP-IR (Ctr-IR, #9330) were obtained from the Bloomington Stock Center. Transgenic RNAi fly lines bearing UAS-CG31148-IR-a (UAS-dGBA1a-IR-a, #14697), UAS-CG31148-IR-b (UAS-dGBA1a-IR-b, #14698), UAS-CG31414-IR-a (UAS-dGBA1b-IR-a, #21337),
UAS-CG31414-IR-b (UAS-dGBA1b-IR-b, #101212), UAS-CG31414-IR-c (UAS-dGBA1b-IR-c, #21336), UAS-CG9092-IR-a (UAS-dβ-Gal-IR-a, #51445), and UAS-CG9092-IR-b
(UAS-dβ-Gal-IR-b, #51446) were obtained from the Vienna Drosophila Research Center
Transgenic fly lines bearing GMR-GAL4 have been described previously (49) . Male flies were 15 used in all the experiments.
GCase activity assay.
Ten fly brains were homogenized in 60 μl lysis buffer (0.25% Taurousodeoxycholic 
qRT-PCR.
Total RNA was isolated from the brains of 1-week-old flies (5 brains per sample). Reverse transcription and real-time PCR were performed as described previously (50) . The sequences of the forward and reverse primers were as follows:
Rpl32 forward, 5′-AGCGCACCAAGCACTTCATCCGCCA-3′
Rpl32 reverse, 5′-GCGCACGTTGTGCACCAGGAACTTC-3′
dβ-Gal forward, 5′-TGCTGAGCGAGATAATGGTG-3′
dβ-Gal reverse, 5′-ATACCACTTGCCCACCTCTG-3′
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Climbing assay.
The climbing assay was performed according to a published protocol (51) 
TLC analysis.
Glycosphingolipid extraction and TLC analysis were performed as described previously (53, 54) with slight modifications. 
Statistical analyses.
Quantitative data are expressed as the mean ± S.E. The statistical differences between 2 groups were analyzed by the two-tailed Student's t-test. For comparison between more than 2 groups, one-way or two-way ANOVA was followed by the Bonferroni test. Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software). 
